66th ASH Annual Meeting: 702. CAR-T Cell Therapies: Basic and Translational: Enhancements in CAR-T Cell Signaling, Delivery & Manufacturing

Symposia: CAR-T Cell Therapies: Basic and Translational Oral and Poster Abstracts
Oral

Research, Lymphoid Leukemias, Combination therapy, Fundamental Science, ALL, Translational Research, Lymphomas, Non-Hodgkin lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, B Cell lymphoma, T Cell lymphoma, Diseases, Treatment Considerations, Biological therapies, Immunology, Aggressive lymphoma, Immunotherapy, Lymphoid Malignancies, Biological Processes, Myeloid Malignancies, Technology and Procedures

Room 6A (San Diego Convention Center)

Moderators:

Laura Evgin, PhD, BC Cancer Research Institute and Sarwish Rafiq, PhD,

Disclosures:

No relevant conflicts of interest to declare.

The abstracts in this session will highlight the various techniques that are being investigated to improve the signaling, delivery, and manufacturing of CAR T cells.

9:30 AM

499

Selective Support of CAR-T Cell Therapies By Cis-Targeted IL-2 Enhances Anti-Tumor Activity and Obviates the Need for Lymphodepletion in Non-Human Primates

Sara Sleiman¹^*, Tyler Hansen, MS¹^*, Nathan D Mathewson, PhD², Feng Shen, MD, PhD¹^*, Miroslaw Kozlowski, PhD¹^*, Olga Shestova, PhD¹^*, Maksim Shestov¹^*, Danuta Jarocha, PhD¹^*, Vanessa Gonzalez¹^*, Joseph A. Fraietta, PhD¹^*, Hannah Thomas³^*, Jack Swain³^*, Raimon Duran-Struuck, PhD, DVM³^*, Kelly D. Moynihan, PhD²^*, Paul Bessette²^*, Chris Kimberlin²^*, Meghana Sukthankar²^*, Terrence Park²^*, Andy Yeung, PhD²^*, Ivana Djuretic, PhD²^* and Saar Gill, MD, PhD^1,4

¹Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
²Asher Biotherapeutics, South San Francisco, CA
³Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA
⁴University of Pennsylvania, Philadelphia, PA

9:45 AM

500

CD5 Elimination Enhances CART Cell Proliferation through JAK-STAT Activation

Trang Vu, PhD¹^*, Ruchi P. Patel, PhD¹, Steven Yang, M.D, Ph.D.¹^*, Dean Qian, M.S.¹^*, Stefan K. Barta, MD^2,3, Nicholas A. Siciliano, PhD¹^*, Marco Ruella, MD^4,5 and Adam E. Snook, PhD¹^*

¹Vittoria Biotherapeutics, Philadelphia, PA
²Abramson Cancer Center, The Fox Chase Cancer Center Foundation, Philadelphia, PA
³Division of Hematology-Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA
⁴Institute for Immunology and Immune Health University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA, Philadelphia
⁵Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

10:00 AM

501

Dual-Vector-Transduction with Single-Step Magnetic Selection (Zip-sort) Increases Transgenic Payloads to Enhance CAR T Cell Activity

Scott E. James, MD, PhD¹, Sophia Chen, MD¹^*, Brandon Ng, PhD²^*, Jacob Fischman²^*, Lorenz Jahn, PhD²^*, Alexander P. Boardman, MD³^*, Adhithi Rajagopalan, PhD¹^*, Harold K Elias, MD², Alyssa R Massa¹^*, Dylan Manuele²^*, Katherine Nichols²^*, Amina Lazrak²^*, Nicole Lee²^*, Aoife Doto, PhD⁴^*, Alexander McMarland, PhD⁴^*, Angelina Petrichenko⁴^*, John Everett, PhD⁴^*, Frederic Bushman, PhD⁴^*, Teng Fei, PhD⁵^*, Anastasia Kousa, PhD¹^*, Andri Leo L Lemarquis, MD, PhD¹^*, Susan DeWolf, MD⁶^*, Jonathan U. Peled, MD, PhD⁷, Santosha A. Vardhana, MD, PhD³, Christopher A. Klebanoff, MD⁸^* and Marcel R.M. van den Brink, MD, PhD⁹

¹City of Hope National Medical Center, Duarte, CA
²Memorial Sloan Kettering Cancer Center, New York, NY
³Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Department of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
⁵Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
⁶Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY
⁷Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY
⁸Memorial Sloan Kettering Cancer Center, New York
⁹Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA

10:15 AM

502

Vivovec™ Surface-Engineered Lentiviral Particles Mediate In Vivo CAR T Generation with Potent and Highly Durable Activity in Non-Human Primates

Maura H. Parker, PhD¹^*, Kristen L. Mittelsteadt, PhD¹^*, Justin T. Ulrich-Lewis, PhD¹^*, Weiliang Tang, PhD¹^*, Mollie M. McDonnell, PhD¹^*, Richard Manivanh, PhD¹^*, Alissa H. Brandes¹^*, Nolan Ericson, BSc¹^*, Angela Soo Min Koo, BSc¹^*, Greyson Hamilton, BSc¹^*, Yong Ha Youn¹^*, Chang-Chih Wu, PhD¹^*, Seungjin Shin, PhD¹^*, Rebecca J Gottschalk, MSc¹^*, Kelsey L Lynch, PhD¹^*, Eric Cavanaugh, PhD²^*, Hans-Peter Kiem, MD, PhD², Andrew M. Scharenberg, MD¹^*, Ryan P. Larson, PhD¹^*, Laurie O. Beitz, MD¹^* and Byoung Y. Ryu, PhD¹

¹Umoja Biopharma, Seattle, WA
²Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA

10:30 AM

503

Alloimmune Defense Receptor Combined with Genetic Ablation of Adhesion Ligand CD58 Is a Comprehensive Approach to Promote Functional Persistence of Allogeneic Cell Therapies without Conditioning Chemotherapy

Alan Williams, PhD¹^*, Rina Mbofung, PhD¹^*, Daniel Morales-Mantilla, PhD¹^*, Brian Groff¹^*, Alison O'Connor, MS¹^*, Binzhong Li²^*, Ramesh Janani³^*, Betsy Rezner¹^*, Mark Jelcic, PhD¹^*, Yijia Pan, PhD¹^*, Tom Lee, PhD¹^*, Karl-Johan Malmberg⁴^*, Maksim Mamonkin, PhD⁵, John Goulding¹^*, Jode Goodridge, PhD¹^* and Bahram Valamehr, PhD¹

¹Fate Therapeutics, San Diego, CA
²Fate Therapeutics, San Diego
³Fate Therapeutics, san diego
⁴Karolinska Institutet Karolinska Univ. Hosp. Huddinge, Stockholm, SWE
⁵Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX

10:45 AM

504

Overcoming the Lack of CD2:CD58 Costimulation in Chimeric Antigen Receptor T-Cell Immunotherapies

Alberto Carturan¹^*, Mathew G. Angelos, MD, PhD^1,2,3, Raymone Pajarillo, MS¹^*, Jesse Rodriguez¹^*, Jaryse Harris, MD⁴^*, Yunlin Zhang, MS¹^*, Ekta Singh, BS¹^*, Andrew Lee¹^*, Ositadimma Ugwuanyi, BS¹^*, Ruchi P. Patel, PhD^1,5, Puneeth Guruprasad⁶, Jean Lemoine^1,7^*, Jong Hyun Cho⁸^*, Patrizia Porazzi, PhD^1,9,10^*, Stephen J. Schuster, MD^1,9,10,11 and Marco Ruella, MD^1,9,10,11

¹Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
²Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Denver, CO
³Division of Hematology, University of Colorado School of Medicine, Aurora, CO
⁴Department of Pathology, University of Pennsylvania, Philadelphia, PA
⁵Vittoria Biotherapeutics, Philadelphia, PA
⁶Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, North Wales, PA
⁷Hopital Saint-Louis, Paris, France
⁸Department of Pathology, Immunology and Laboratory Medicine, Rutgers New Jersey Medical School, Newark
⁹Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA
¹⁰Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
¹¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

702.O4.6 702. CAR-T Cell Therapies: Basic and Translational: Enhancements in CAR-T Cell Signaling, Delivery & Manufacturing